On September 4, for the first time in its 200-year history, The Lancet (Authoritative academic Journal of Global Medicine) published a report on the clinical trials of a China-made device, the Firehawk stent, which was independently developed by the Shanghai-based MicroPort Scientific Corporation (hereinafter referred to as “MicroPort”). According to the research results of large-scale clinical trials in Europe, the study has resolved the major problems in the field of cardiovascular intervention which have plagued the world for more than 10 years.
Hirehawk in the Lancet
It is proven that the implantation of Firehawk, as the third-generation targeted drug-eluting stent, helps the treated vascular area heal quickly at the early stage. Because of its innovative design of drugs contained in micro grooves, biodegradable polymer and lower drug loading (only one-third of that of the similar products can achieve the same effect), it greatly improves the safety, effectively reduces the occurrence of late thrombotic events. It stands at the top of the tech heap in the world.
After 15 years of repeated design and comparison, the Firehawk R&D team selected and reached the most technically difficult solution – drugs contained in micro-grooves, by laser grooving on the surface of the metal stent and then filling the grooves with drugs. Its differences from the conventional technology include: grooves can prevent the coating from falling off during delivery and drug loss; drugs can be accurately released from the corresponding grooves after reaching the vascular lesion area, thereby greatly improving effectiveness and avoiding waste.
